Pharma sector Q3FY24 review: A mixed quarter, India business sees sharp recovery; what is next?
For the full FY24, Axis Securities analysts anticipate high single-digit growth for the sector on the back of the US business largely holding up its strong momentum, margins sustaining and, in some cases, even improving, and the domestic business recovering.
Pharma sector Q3FY24 review: As the third quarter (Q3 FY24) earnings season comes to a close, the analysis of different companies' and sectors' performance is on everyone's radar. As regards the pharmaceutical industry, analysts note that the companies in the sector have overall put up a mixed show for the October–December period.
stock market updates here. For all other news related to business, politics, tech and auto, visit Zeebiz.com.
DISCLAIMER: The views and investment tips expressed by investment experts on zeebiz.com are their own and not those of the website or its management. zeebiz.com advises users to check with certified experts before making any investment decisions.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.